DMC Biotechnologies, Inc. Awarded Competitive Grant from the U.S. Department of Agriculture National Institute of Food and Agriculture

Friday, October 20, 2017

DMC Biotechnologies, Inc. (, an early-stage biotechnology company,has been awardeda U.S. Department of Agriculture National Institute of Food and Agriculture (USDA NIFA) Small Business Innovation Research (SBIR)Phase Igrantfor $100,000 to commercialize their proprietary high throughput metabolic engineering platform that enables the rapid development of microbial hosts for the production of a broad diversity of bio-based products.

The USDA SBIR program is a highly competitive program which seeks to transform early-stage scientific discovery into societal and economic benefit by catalyzing private sector commercialization of technological innovations.

Biology is fundamentally a manufacturing language with massive potential to positively impact our world. Increased deployment of bio-based products can reduce our dependence on foreign oil, improve the nutrition of the foods that we eat, provide domestic manufacturing of existing products, and enable new-to-the world materials that are only accessible using the precision of biology. DMC makes bio-based products using enhanced microbial fermentation. We are building a capital-efficient, multi-product company using our patent-pending technology that overcomes key barriers that have historically impeded efforts in this sector.

“For small agricultural businesses, the federal government is a key, initial investor to help them get great ideas into the marketplace,” said NIFA Director, Sonny Ramaswamy. “The feasibility and scalability of these business concepts are evaluated through our peer review process, and businesses get to keep their intellectual property rights as they commercialize their ventures.”

“The vision for DMC is to develop bio-based processes that are superior in cost and quality to existing manufacturing routes. We are pleased to be recognized with this highly competitive award from the USDA and are grateful for their support of our mission.This SBIR grant plays a vital role in advancing our technology along the commercial path,” said Matt Lipscomb, Ph.D., CEO and Co-Founder of DMC.

The Small Business Innovation Research Program (SBIR) is coordinated by the Small Business Administration and administered by 11 federal agencies, including USDA. It encourages domestic small businesses to engage in high-growth research and development with high potential for commercialization and that could lead to significant public benefit. Phase I grants invest in feasibility and proof of concept studies. Phase II grants help successful Phase I projects scale up, implement, and commercialize their ventures. Topic areas include forests and related resources; plant production and protection – biology; animal production and protection; air, water, and soils; food science and nutrition; rural and community development; aquaculture; biofuels and biobased products; small and mid-size farms; and plant production and protection – engineering.

To learn more about the USDA SBIR/STTR program, visit:

Continue Reading

Diversity Suits the C-Suite

Wednesday, October 18, 2017


Collaborative by Nature

Tuesday, October 10, 2017


Flagship Biosciences Provides Analytically Validated Tools to Assist in the Analysis of Summits PhaseOut DMD Clinical Trial

Thursday, October 05, 2017

CLSI compliant analytically validated cTA™ tools for 2 duplex IHC assays presented at the 22nd annual meeting of the World Muscle Society

Continue Reading

MBC Pharma Inc. Awarded a SBIR Phase II Grant to Further Develop a Novel Bone-Targeted Combination Treatment for Osteosarcoma

Thursday, October 05, 2017

MBC Pharma Inc., a privately held biopharmaceutical company announced today, that it has been awarded an $2M Phase II Small Business Innovation Research (SBIR) grant from the U.S. National Institutes of Health. MBC will use this 2-year grant to build upon the success of the Phase I grant—demonstration of in vivo efficacy in model systems of osteosarcoma. The new work will focus on optimizing the method of use and testing the drug combination in spontaneous canine osteosarcoma.  

Smart, Hard-Working and Happy

Monday, October 02, 2017


2017 Rocky Mountain Life Science Investor and Partnering Conference welcomes 40 investors and strategic partners

Friday, September 29, 2017


AlloSource Strives to Advance Healing

Tuesday, September 26, 2017


dBMEDx Announces Supply Agreement with Direct Supply

Monday, September 25, 2017

dBMEDx, Inc., a privately-held, wireless medical device company, announced today that it has entered into a definitive supply agreement with Direct Supply®, the nation’s leading provider of equipment for the Senior Living market. Under the agreement, dBMEDx will integrate their proprietary bladder scanning technology into a new Direct Supply® device to create the first wireless bladder scanner optimized for use in long term care settings.
Continue Reading

AmideBio Awarded NIH SBIR Phase 1 Grant to Study Novel Glucagon for the Treatment of Hyperinsulinism

Monday, September 25, 2017

AmideBio, LLC, a privately-held biopharmaceutical company, announced today that it has received a $338,387 Phase 1 Small Business Innovation Research (SBIR) grant from the National Institute of Health. Under the 2 year grant, AmideBio will develop and produce a series of solution-stable glucagons and test them both in vitro and in vivo with the goal of identifying a glucagon analog suitable for clinical testing for long term treatment of hyperinsulinism, a disease whereby infants and new born babies suffer from persistant hypoglycemia which can lead to seizures and brain damage. A solution-stable glucagon would also have benefit in the treatment of emergency hypoglycemia.

Glucagon has been shown to be an effective treatment option for hyperinsulinism but its inherent instability has limited its therapeutic use due to complications associated with its administration through pumps. Using AmideBio’s BioPure™ process, the Company has produced glucagon analogs that have in-use stability of at least 6 months at 40°C and extended long term storage that meets the standard 95% potency requirement throughout 2-year storage at 4°C. These analogs will be suitable for use in a pump system for long-term management of severe persistent hyperinsulinism. Under the grant, these analogs will be further refined and tested.

“This grant will allow us to further develop and test AmideBio’s stable glucagons for treatment of patients with hyperinsulinism who fail to respond to current drug treatments,” said Misha Plam, CEO of AmideBio. “This therapeutic solution offers the potential for babies to avoid traumatic surgeries including a total pancreatectomy, providing the chance for them to live more normal lives.”

Continue Reading